Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $261 | $365 | $720 | $794 |
| - Cash | $0 | $21 | $42 | $100 |
| + Debt | $0 | $2,666 | $2,211 | $1,857 |
| Enterprise Value | $261 | $3,010 | $2,888 | $2,550 |
| Revenue | $1,371 | $859 | $291 | $171 |
| % Growth | 59.7% | 194.8% | 70.5% | – |
| Gross Profit | $497 | $365 | $157 | $17 |
| % Margin | 36.2% | 42.6% | 54.1% | 10% |
| EBITDA | $14 | -$1 | -$169 | -$402 |
| % Margin | 1% | -0.1% | -58% | -235.3% |
| Net Income | -$3,236 | -$2,092 | $321 | $1,259 |
| % Margin | -236% | -243.7% | 110.2% | 737% |
| EPS Diluted | -0.016 | -0.011 | 0.002 | 0.012 |
| % Growth | -41.2% | -733.3% | -85.1% | – |
| Operating Cash Flow | – | -$318 | -$93 | -$105 |
| Capital Expenditures | – | -$127 | -$188 | -$137 |
| Free Cash Flow | – | -$444 | -$281 | -$242 |